Phase II Preventing Mesothelioma Progression

What to Expect:

The trial has two arms. In the experimental arm, patients will receive anetumab ravtansine to test its effects on mesothelioma. In the comparator arm, patients will receive vinorelbine so that researchers can compare the results of the experimental arm to another drug. Patients will either receive anetumab ravtansine every three weeks or vinorelbine every week.

Blood tests and tumor assessments will be performed throughout the treatment to monitor the patient’s health and progress. Treatment will continue until the patient has disease progression or until they meet other criteria to be able to withdraw from the study. Efficacy will be measured by the rate of progression free survival.

Experimental Arm

Patients in the experimental arm will receive anetumab ravtansine as an IV infusion for 1 hour every 3 weeks. The treatment will continue until the patient has disease progression or withdraws for another reason.

Comparator Arm

Patients in the active comparator arm of the experiment will receive vinorelbine through an IV for 6 to 10 minutes weekly. Treatments will continue until the patient has disease progression or withdraws from the trial.

Who Is This Trial For?

This clinical trial is available to patients with malignant pleural mesothelioma who have tried standard first line chemotherapy but did not see results.

General eligibility criteria includes:

• Diagnosed pleural mesothelioma
• Overexpression of the mesothelin protein
• Did not improve after receiving standard chemotherapy
• Healthy heart

Locations

There are 76 different locations around the world participating in this clinical trial. Of those 76, there are 19 locations spread throughout the United States.

There are locations in these states: California, Colorado, Connecticut, Florida, Illinois, Louisiana, Maryland, Michigan, Minnesota, New York, North Carolina, Ohio, Pennsylvania, and Texas.

Enrolling in This Trial

In phase I, anetumab ravtansine had amazing results on the participants in the trial. Now, phase II is recruiting pleural mesothelioma patients. Contact us for more information about participating in this clinical trial or others. Get connected to this clinical trial today.